Clinical impact of amotosalen‐ultraviolet A pathogen‐inactivated platelets stored for up to 7 days-Reference-Cited by-同舟云学术

Clinical impact of amotosalen‐ultraviolet A pathogen‐inactivated platelets stored for up to 7 days

Published:2019-10 Issue:11 Volume:59 Page:3350-3361
ISSN:0041-1132
Container-title:Transfusion
language:en
Short-container-title:Transfusion

Author:

Infanti Laura¹,Holbro Andreas¹²,Passweg Jakob²,Bolliger Daniel³,Tsakiris Dimitrios A.²,Merki Ramona²,Plattner Alexandra¹,Tappe David⁴,Irsch Johannes⁴,Lin Jin‐Sying⁴,Corash Laurence⁴^ORCID,Benjamin Richard J.⁴,Buser Andreas¹²^ORCID

Affiliation:

1. Regional Blood Transfusion Service Swiss Red Cross Basel Switzerland

2. Hematology University Hospital Basel, University of Basel Basel Switzerland

3. Department for Anesthesia, Prehospital Emergency Medicine, and Pain Therapy University Hospital Basel, University of Basel Basel Switzerland

4. Cerus Corporation Concord California

Publisher

Wiley

Subject

Hematology,Immunology,Immunology and Allergy

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/trf.15511

Reference32 articles.

1. Nationwide Implementation of Pathogen Inactivation for All Platelet Concentrates in Switzerland

2. RueschM JutziM StollerR. 2 years experience with pathogen inactivation for all platelet concentrates in Switzerland. 2014. [cited 2014 Dec 1]. Available from:https://www.swissmedic.ch/marktueberwachung.

3. Pathogen-inactivation of platelet components with the INTERCEPT Blood System™: A cohort study

4. Comparison of transfusion efficacy of amotosalen-based pathogen-reduced platelet components and gamma-irradiated platelet components

5. Hemovigilance monitoring of platelet septic reactions with effective bacterial protection systems

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Platelet Pathogen Reduction Technology—Should We Stay or Should We Go…?;Journal of Clinical Medicine;2024-09-10

2. Acute pulmonary injury in hematology patients supported with pathogen-reduced and conventional platelet components;Blood Advances;2024-05-14

3. Evaluation of bacterial safety approaches of platelet blood concentrates: bacterial screening and pathogen reduction;Frontiers in Medicine;2024-04-05

4. Increase of Phosphoprotein Expressions in Amotosalen/UVA-Treated Platelet Concentrates;Transfusion Medicine and Hemotherapy;2024

5. Biochemical and functional characteristics of stored (double‐dose) buffy‐coat platelet concentrates treated with amotosalen and a prototype UVA light‐emitting diode illuminator;Transfusion;2023-08-24